Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells

Breast Cancer Research

Volumn 16, Issue 5, 2014, Pages

  Liu, Chun Yu ^a,b   Hung, Man Hsin ^a,b   Wang, Duen Shian ^a   Chu, Pei Yi ^c   Su, Jung Chen ^b   Teng, Tsung Han ^e,f   Huang, Chun Teng ^b,g   Chao, Ting Ting ^h   Wang, Cheng Yi ^h   Shiau, Chung Wai ^b   Tseng, Ling Ming ^a,b   Chen, Kuen Feng ^d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c St Martin De Porres Hospitals   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^f Taichung Hospital   (Taiwan)

^g TAIPEI CITY HOSPITAL   (Taiwan)

^h FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; OKADAIC ACID; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SMALL INTERFERING RNA; TAMOXIFEN CITRATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AUTOANTIGEN; ESTROGEN RECEPTOR; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; TAMOXIFEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETIC TRANSCRIPTION; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AUTOANTIGENS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MICE, NUDE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908092772     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0431-9     Document Type: Article

References (60)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 11553815.
2. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
4. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26:2373-2378. 10.1200/JCO.2007.14.4287, 18413639.
5. Huang CS, Lin CH, Lu YS, Shen CY. Unique features of breast cancer in Asian women-breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol 2010, 118:300-303. 10.1016/j.jsbmb.2009.12.017, 20045728.
6. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277. 10.1200/JCO.2009.25.9820, 20498394.
7. Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S, Marotti L, Penault-Llorca F, Kotti-Kitromilidou AM, Rodger A, Harbeck N. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012, 48:3355-3377. 10.1016/j.ejca.2012.10.004, 23116682.
8. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BME, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013, 11:753-760. 23847214.
9. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007, 130:21-24. 10.1016/j.cell.2007.06.034, 17632053.
10. Switzer CH, Ridnour LA, Cheng RY, Sparatore A, Del Soldato P, Moody TW, Vitek MP, Roberts DD, Wink DA. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene 2009, 28:3837-3846. 10.1038/onc.2009.244, 19701246.
11. Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 2013, 335:9-18. 10.1016/j.canlet.2013.02.036, 23454242.
12. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001, 353:417-439. 10.1042/0264-6021:3530417, 11171037.
13. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004, 6:171-183. A published erratum appears in Cancer Cell 2013, 24:394-398, 10.1016/j.ccr.2004.07.009, 15324700.
14. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009, 284:11121-11133. 10.1074/jbc.M806268200, 19261616.
15. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA, Hahn WC. The tumor suppressor PP2A Aβ regulates the RalA GTPase. Cell 2007, 129:969-982. 10.1016/j.cell.2007.03.047, 17540176.
16. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J. CIP2A inhibits PP2A in human malignancies. Cell 2007, 130:51-62. 10.1016/j.cell.2007.04.044, 17632056.
17. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009, 15:5092-5100. 10.1158/1078-0432.CCR-08-3283, 19671842.
18. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011, 18:857-865. 10.1245/s10434-010-1313-8, 20842459.
19. Fang Y, Li Z, Wang X, Zhang S. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol 2012, 33:2299-2306. 10.1007/s13277-012-0492-2, 22923389.
20. Li W, Ge Z, Liu C, Liu Z, Bjorkholm M, Jia J, Xu D. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 2008, 14:3722-3728. 10.1158/1078-0432.CCR-07-4137, 18559589.
21. Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29:136. 10.1186/1756-9966-29-136, 20964854.
22. Wang J, Li W, Li L, Yu X, Jia J, Chen C. CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011, 33:290-298. 10.1111/j.1751-553X.2010.01288.x, 21219591.
23. Choi YA, Park JS, Park MY, Oh KS, Lee MS, Lim JS, Kim KI, Kim KY, Kwon J, Yoon DY, Moon EY, Yang Y. Increase in CIP2A expression is associated with doxorubicin resistance. FEBS Lett 2011, 585:755-760. 10.1016/j.febslet.2011.01.018, 21241697.
24. Liu CY, Shiau CW, Kuo HY, Huang HP, Chen MH, Tzeng CH, Chen KF. Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells. Haematologica 2013, 98:729-738. 10.3324/haematol.2011.050187, 22983581.
25. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012, 14:R68. 10.1186/bcr3175, 22537901.
26. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618. 10.1056/NEJM199811263392207, 9828250.
27. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0.
28. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46(12 Suppl):2884-2888. 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U, 7448733.
29. Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Greenberg CS, Dewhirst MW. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 2000, 6:4359-4364. 11106254.
30. Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002, 277:45695-45703. 10.1074/jbc.M208092200, 12244117.
31. Zhao R, Leung E, Grüner S, Schapira M, Houry WA. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One 2010, 5:e9934. 10.1371/journal.pone.0009934, 20376192.
32. Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PLoS One 2013, 8:e60889. 10.1371/journal.pone.0060889, 23593342.
33. Shanle EK, Zhao Z, Hawse J, Wisinski K, Keles S, Yuan M, Xu W. Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells. Mol Endocrinol 2013, 27:1762-1775. 10.1210/me.2013-1164, 23979844.
34. Khanna A, Okkeri J, Bilgen T, Tiirikka T, Vihinen M, Visakorpi T, Westermarck J. ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. PLoS One 2011, 6:e17979. 10.1371/journal.pone.0017979, 21445343.
35. Pallai R, Bhaskar A, Sodi V, Rice LM. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 2012, 3:323-335. 10.4161/trns.22518, 23117818.
36. Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernila P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012, 31:4266-4278. 10.1038/onc.2011.599, 22249265.
37. Leung YK, Lee MT, Lam HM, Tarapore P, Ho SM. Estrogen receptor-β and breast cancer: translating biology into clinical practice. Steroids 2012, 77:727-737. 10.1016/j.steroids.2012.03.008, 22465878.
38. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M. Estrogen receptor β expression is associated with tamoxifen response in ERα-negative breast carcinoma. Clin Cancer Res 2007, 13:1987-1994. 10.1158/1078-0432.CCR-06-1823, 17404078.
39. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G. Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008, 26:3727-3734. 10.1200/JCO.2007.14.2968, 18669459.
40. Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F, Liu M. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma. Med Oncol 2013, 30:406. 10.1007/s12032-012-0406-6, 23275123.
41. Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol 2012, 48:585-593. 10.1016/j.oraloncology.2012.01.012, 22342571.
42. Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma. Biochem Pharmacol 2013, 85:356-366. 10.1016/j.bcp.2012.11.009, 23178652.
43. Ma L, Wen ZS, Liu Z, Hu Z, Ma J, Chen XQ, Liu YQ, Pu JX, Xiao WL, Sun HD, Zhou GB. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 2011, 6:e20159. 10.1371/journal.pone.0020159, 21655278.
44. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29:6257-6266. 10.1038/onc.2010.357, 20729919.
45. Chen KF, Pao KC, Su JC, Chou YC, Liu CY, Chen HJ, Huang JW, Kim I, Shiau CW. Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorg Med Chem 2012, 20:6144-6153. 10.1016/j.bmc.2012.08.039, 22980218.
46. Jung HM, Patel RS, Phillips BL, Wang H, Cohen DM, Reinhold WC, Chang LJ, Yang LJ, Chan EK. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol Biol Cell 2013, 24:1638-1648. 10.1091/mbc.E12-12-0891, 23552692.
47. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, Lee H. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 2013, 19:4092-4103. 10.1158/1078-0432.CCR-12-3439, 23743567.
48. Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, Hou DR, Chen PJ, Cheng AL. Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther 2011, 10:892-901. 10.1158/1535-7163.MCT-10-0794, 21393428.
49. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Soliman H, Somlo G, Theriault RL, Ward JH, Wolff AC, Zellars R, Kumar R, Shead DA. Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012, 10:821-829. 22773798.
50. Schmale I, Liu S, Rayhanabad J, Russell CA, Sener SF. Ductal carcinoma in situ (DCIS) of the breast: perspectives on biology and controversies in current management. J Surg Oncol 2012, 105:212-220. 10.1002/jso.22020, 21751217.
51. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007, 99:283-290. 10.1093/jnci/djk050, 17312305.
52. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, Chen KF. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett 2012, 317:9-15. 10.1016/j.canlet.2011.11.005, 22085493.
53. Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem 2003, 36:247-253. 10.1016/S0009-9120(03)00007-9, 12810152.
54. Pearson OH, Manni A, Arafah BM. Antiestrogen treatment of breast cancer: an overview. Cancer Res 1982, 42(8 Suppl):3424s-3429s. 7044524.
55. Osborne CK, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985, 45:584-590. 3967234.
56. Gottardis MM, Robinson SP, Jordan VC. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988, 30:311-314. 10.1016/0022-4731(88)90113-6, 3386259.
57. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988, 48:812-815. 3338079.
58. Iino Y, Wolf DM, Langan-Fahey SM, Johnson DA, Ricchio M, Thompson ME, Jordan VC. Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br J Cancer 1991, 64:1019-1024. 10.1038/bjc.1991.457, 1764361.
59. Robinson SP, Langan-Fahey SM, Jordan VC. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol 1989, 25:1769-1776. 10.1016/0277-5379(89)90347-7, 2632258.
60. Perrotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 2013, 14:e229-e238. 10.1016/S1470-2045(12)70558-2, 23639323.